End-of-day quote
Other stock markets
|
||
- USD | - |
May. 09 | HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance | MT |
May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Financials (USD)
Sales 2024 * | 60.29B | Sales 2025 * | 62.64B | Capitalization | 160B |
---|---|---|---|---|---|
Net income 2024 * | 7.18B | Net income 2025 * | 11.14B | EV / Sales 2024 * | 3.61 x |
Net Debt 2024 * | 58.11B | Net Debt 2025 * | 49.97B | EV / Sales 2025 * | 3.35 x |
P/E ratio 2024 * |
20.2
x | P/E ratio 2025 * |
13.9
x | Employees | - |
Yield 2024 * |
5.91% | Yield 2025 * |
6% | Free-Float | 59.01% |
Latest transcript on Pfizer Inc
Managers | Title | Age | Since |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 92-12-31 |
David Denton
DFI | Director of Finance/CFO | 59 | 22-05-01 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 19-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 20-03-31 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 17-02-22 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 13-09-26 |
1st Jan change | Capi. | |
---|---|---|
+32.36% | 695B | |
+26.51% | 568B | |
-4.40% | 361B | |
+19.46% | 330B | |
+3.50% | 283B | |
+16.34% | 239B | |
+6.68% | 204B | |
-9.08% | 198B | |
+8.62% | 168B |